Sobhan Oncology Pharmaceutical Company (DSANKO) income statement
Operating revenue through to net profit and earnings per share
- Ticker
- DSANKO
- Industry
- Pharmaceuticals
- Market
- Iran Fara Bourse
Latest periods
| Item | To 1405/06/31 | To 1404/06/31 | To 1403/06/31 | To 1402/06/31 | To 1401/06/31 | To 1400/09/30 |
|---|---|---|---|---|---|---|
| Operating revenue | 7,898,917 | 3,762,309 | 4,079,983 | 4,997,331 | 3,267,903 | 4,310,743 |
| Cost of operating revenue | -2,313,702 | -2,378,624 | -2,158,151 | -2,546,307 | -1,958,960 | -2,474,580 |
| Gross profit (loss) | 5,585,215 | 1,383,685 | 1,921,832 | 2,451,024 | 1,308,943 | 1,836,163 |
| Selling, general and administrative expenses | -1,723,085 | -893,379 | -369,265 | -629,702 | -291,964 | -284,675 |
| Other income | 167,635 | 197,452 | 34,240 | 106,274 | 18,306 | 1,486 |
| Other expenses | -1,531,479 | -351,549 | -866,771 | -489,414 | -49,282 | -481,335 |
| Operating profit (loss) | 2,498,286 | 336,209 | 720,036 | 1,438,182 | 986,003 | 1,071,639 |
| Finance costs | -1,837,887 | -1,197,585 | -1,136,718 | -673,100 | -596,570 | -543,804 |
| Other non-operating income and expenses | -90,431 | 984,584 | 32,384 | 15,708 | 5,064 | -57,315 |
| Profit (loss) from continuing operations before tax | 569,968 | 123,208 | -384,298 | 780,790 | 394,497 | 470,520 |
| Current year tax | -174,100 | -27,722 | 0 | -126,488 | -98,624 | -92,762 |
| Net profit (loss) from continuing operations | 204,366 | 17,486 | -384,298 | 654,302 | 295,873 | 320,588 |
| Net profit (loss) | 204,366 | 17,486 | -384,298 | 654,302 | 295,873 | 320,588 |
| Basic earnings (loss) per share | 34 rials | 3 rials | -206 rials | 417 rials | 247 rials | 257 rials |
| Net earnings (loss) per share, rials | 35 rials | 3 rials | -201 rials | 407 rials | 226 rials | 334 rials |
| Capital | 6,000,000 | 6,000,000 | 1,911,000 | 1,611,000 | 1,311,000 | 961,000 |
Reporting periods
57 periods are on file for this report, from the period ending 1393/12/29 to the period ending 1405/06/31.